Results 51 to 60 of about 49,931 (273)

The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?

Cancer Management and Research, 2021
Michael Patrick Lux, 1 Oriana Ciani, 2 William CN Dunlop, 3 Andrea Ferris, 4 Michael Friedlander 5 1Department of Gynecology and Obstetrics, Frauenklinik St. Louise Paderborn, St. Josefs-Krankenhaus Salzkotten, Frauen- und Kinderklinik St.
Lux MP, Ciani O, Dunlop WCN, Ferris A, Friedlander M   +4 more
doaj  

Surrogate outcome measures

, 2022
A surrogate endpoint is a biomarker intended to substitute for a clinical endpoint that should predict clinical benefit or harm or lack of both (definition by National Institute of Health working group). A valid surrogate measure should aid the diagnosis
School of Medicine, Dentistry and Biomedical Sciences, Verghis, Rejina   +1 more
core   +1 more source

Structural insights and therapeutic targets in Acinetobacter baumannii capsule biosynthesis

FEBS Letters, EarlyView.
Hypervirulent KL49 A. baumannii's capsular polysaccharide contains the nonulosonic acid 8‐epi‐Leg5,7Ac2, synthesized by epimerization via ElaA, ElaB, and ElaC. Crystal structures of ElaA, ElaB, and ElaC reveal their role in CMP‐Leg5,7Ac2 synthesis and regioselective C8 epimerization.
Woo Cheol Lee, Junho Jeong, Chae Yeong Lee, Hyunjoon Cho, Man Hwan Oh, Je Chul Lee, Jee‐Young Lee, Yangmee Kim   +7 more
wiley   +1 more source

Validation of a longitudinally measured surrogate marker for a time-to-event endpoint

, 2003
The objective of this paper is to extend the surrogate endpoint validation methodology proposed by Buyse et al. (2000) to the case of a longitudinally measured surrogate marker when the endpoint of interest is time to some key clinical event.
Tomasz Burzykowski, Marc Buyse, Helena Geys, Tony Vangeneugden, Geert Molenberghs, Luc Bijnens, Didier Renard   +6 more
core   +2 more sources

Baseline hazard and survival functions for surrogate endpoint and true endpoint truncated at 8 months using the advanced ovarian cancer meta-analysis dataset.

, 2020
Baseline hazard and survival functions for surrogate endpoint and true endpoint truncated at 8 months using the advanced ovarian cancer meta-analysis dataset.
Casimir Ledoux Sofeu (8367762), Virginie Rondeau (72353)   +1 more
core   +1 more source

Network divergence analysis identifies adaptive gene modules and two orthogonal vulnerability axes in pancreatic cancer

Molecular Oncology, EarlyView.
Tumors contain diverse cellular states whose behavior is shaped by context‐dependent gene coordination. By comparing gene–gene relationships across biological contexts, we identify adaptive transcriptional modules that reorganize into distinct vulnerability axes.
Brian Nelson, Lyanne Delgado‐Coka, Natalia Marchenko, Luisa F. Escobar‐Hoyos, Kenneth R. Shroyer, Alisa Yurovsky, Trey Ideker, Gábor Balázsi, Thomas MacCarthy, Scott Powers   +9 more
wiley   +1 more source

Surrogate Endpoints in Pivotal Clinical Trials for Drug Approval in Japan Compared to the United States

Clinical and Translational Science
Regulatory guidance documents exist on surrogate endpoints in the United States. In Japan, there are no established rules or guidance regarding the use of surrogate endpoints, and various aspects remain unclear.
Yuko Yamamoto, Harumi Kosaka, Hanami Nojiri, Hideki Maeda   +3 more
doaj   +1 more source

Surrogate endpoints in trials: a call for better reporting

Trials, 2022
Using a surrogate endpoint as a substitute for a patient-relevant final outcome enables randomised controlled trials (RCTs) to be conducted more efficiently. However, the use of surrogates remains controversial and there is currently no guideline for the
Oriana Ciani, Anthony M. Manyara, An-Wen Chan, Rod S. Taylor, on behalf of the SPIRIT-SURROGATE/CONSORT-SURROGATE project group   +4 more
doaj   +1 more source

Baseline hazard and survival functions for surrogate endpoint and true endpoint, using simulated meta-analysis of 600 subjects and 30 trials.

, 2020
Baseline hazard and survival functions for surrogate endpoint and true endpoint, using simulated meta-analysis of 600 subjects and 30 trials.
Casimir Ledoux Sofeu (8367762), Virginie Rondeau (72353)   +1 more
core   +1 more source

COMP–PMEPA1 axis promotes epithelial‐to‐mesenchymal transition in breast cancer cells

Molecular Oncology, EarlyView.
This study reveals that cartilage oligomeric matrix protein (COMP) promotes epithelial‐to‐mesenchymal transition (EMT) in breast cancer. We identify PMEPA1 (protein TMEPAI) as a novel COMP‐binding partner that mediates EMT via binding to the TSP domains of COMP, establishing the COMP–PMEPA1 axis as a key EMT driver in breast cancer.
Konstantinos S. Papadakos, Gilar Gorji‐bahri, Lejla Gradjan, Julia Zajac, Kacper Gil, Yvonne Thokozile Nduku, Anna M. Blom   +6 more
wiley   +1 more source